Why do I choose esomeprazole to treat acid-dependent diseases? Artykuł przeglądowy
Article Sidebar
Published:
Nov 30, 2025
Keywords:
proton pump inhibitors, esomeprazole, acid-dependent diseases
Main Article Content
Abstract
Proton pump inhibitors are the strongest medications used in the treatment of acid-dependent gastroenterology diseases that inhibit the secretion of hydrochloric acid in the stomach. The strength of the proton pump inhibitors is different in each patient and is caused by genetic conditions, metabolic differences dependent of cytochrome P450 (CYP) and also dependent of the type of acid inhibitor substance. Esomeprazole is a S-isomer of the omeprazole and it is metabolized in the liver more slowly than omeprazole, the consequence of this process is longer-lasting and higher blood concentration of the medication.
Article Details
How to Cite
Janiak, M. (2025). Why do I choose esomeprazole to treat acid-dependent diseases?. Medycyna Faktow (J EBM), 18(3(68), 386-390. https://doi.org/10.24292/01.MF.0325.08
Issue
Section
Articles
Copyright by Medical Education. All rights reserved.
References
1. Świdnicka-Siergiejko AK, Marek T, Waśko-Czopnik D et al. Diagnostic and therapeutic management in gastroesophageal reflux disease: consensus of the Polish Society of Gastroenterology. Polish Arch Intern Med. 2022; 132: 16196. http://doi.org/10.20452/PAMW.16196.
2. Villoria A, Garcia P, Calvet X et al. Meta-analysis: high-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2008; 28: 868-77.
3. Targownik LE, Fisher DA, Saini SD. Aktualizacja praktyki klinicznej AGA w zakresie odstawiania inhibitorów pompy protonowej: przegląd ekspercki. Gastroenterologia. 2022; 162(4): 1334-42.
4. Zerbib F, Bredenoord AJ, Fass R et al. ESNM/ANMS consensus paper: Diagnosis and management of refractory gastro-esophageal reflux disease. Neurogastroenterol Motil. 2021; 33(4): e14075. http://doi.org/10.1111/nmo.14075.
5. Miner P Jr, Katz PO, Chen Y et al. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol. 2003; 98(12): 2616-20. http://doi.org/10.1111/j.1572-0241.2003.08783.x.
6. Armstrong D, Hungin AP, Kahrilas PJ et al.; International Working Group for the Classification of Oesophagitis (IWGCO). Management of Patients With Refractory Reflux-Like Symptoms Despite Proton Pump Inhibitor Therapy: Evidence-Based Consensus Statements. Aliment Pharmacol Ther. 2025; 61(4): 636-50. http://doi.org/10.1111/apt.18420.
7. Armstrong D. Review article: gastric pH – the most relevant predictor of benefit in reflux disease? Aliment Pharmacol Ther. 2004; 20(Suppl. 5):19-26. http://doi.org/10.1111/j.1365-2036.2004.02140.x.
8. Dąbrowski A. Sytuacje kliniczne preferujące zastosowanie esomeprazolu. Gastroenterologia Praktyczna. 2012; (4).
9. Fossmark R, Johnsen G, Johanessen E et al. Rebound acid hypersecretion after long-term inhibition of gastric acid secretion. Aliment Pharmacol Ther. 2005; 21(2): 149-54.
2. Villoria A, Garcia P, Calvet X et al. Meta-analysis: high-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2008; 28: 868-77.
3. Targownik LE, Fisher DA, Saini SD. Aktualizacja praktyki klinicznej AGA w zakresie odstawiania inhibitorów pompy protonowej: przegląd ekspercki. Gastroenterologia. 2022; 162(4): 1334-42.
4. Zerbib F, Bredenoord AJ, Fass R et al. ESNM/ANMS consensus paper: Diagnosis and management of refractory gastro-esophageal reflux disease. Neurogastroenterol Motil. 2021; 33(4): e14075. http://doi.org/10.1111/nmo.14075.
5. Miner P Jr, Katz PO, Chen Y et al. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol. 2003; 98(12): 2616-20. http://doi.org/10.1111/j.1572-0241.2003.08783.x.
6. Armstrong D, Hungin AP, Kahrilas PJ et al.; International Working Group for the Classification of Oesophagitis (IWGCO). Management of Patients With Refractory Reflux-Like Symptoms Despite Proton Pump Inhibitor Therapy: Evidence-Based Consensus Statements. Aliment Pharmacol Ther. 2025; 61(4): 636-50. http://doi.org/10.1111/apt.18420.
7. Armstrong D. Review article: gastric pH – the most relevant predictor of benefit in reflux disease? Aliment Pharmacol Ther. 2004; 20(Suppl. 5):19-26. http://doi.org/10.1111/j.1365-2036.2004.02140.x.
8. Dąbrowski A. Sytuacje kliniczne preferujące zastosowanie esomeprazolu. Gastroenterologia Praktyczna. 2012; (4).
9. Fossmark R, Johnsen G, Johanessen E et al. Rebound acid hypersecretion after long-term inhibition of gastric acid secretion. Aliment Pharmacol Ther. 2005; 21(2): 149-54.